AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01856907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin-Metformin
Description: Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
Study NCT01856907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Biguanide- insulin sensitizer
Study NCT01856907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Will evaluate effect of lifestyle and diet only
Study NCT01199328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg Tablet oral, once daily
Study NCT01199328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20 mg Tablet oral, once daily
Study NCT03032133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional pain control
Description: Regional pain catheter
Study NCT00385515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
Study NCT03032133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local pain control
Description: Local intraarticular pain catheter
Study NCT01309165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP
Description: CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
Study NCT01309165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Occupational Therapy
Description: Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
Study NCT00006467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT05455164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomalto Oligosaccharide
Description: all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
Study NCT03096067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy slow resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
Study NCT03096067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate slow resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
Study NCT02498691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Blood and saliva samples, placenta and cord blood collection
Study NCT03948607 — intervention group
Intervention type: OTHER
Intervention: Electroencephalography during sustained attention task.
Description: The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3.
Study NCT01572259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Study NCT01572259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interruption of the traitment with growth hormone
Study NCT03949842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
Description: A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
Study NCT01295905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A contact lens
Description: Investigational silicone hydrogel, single vision soft contact lens
Study NCT02769650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study NCT01295905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon B contact lens
Description: Commercially marketed silicone hydrogel, single vision soft contact lens
Study NCT03949842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol
Description: The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
Study NCT02787265 — intervention group
Intervention type: DEVICE
Intervention: spinal cord stimulation
Study NCT00285818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone is a glucocorticoid receptor antagonist.
Study NCT00285818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo is a capsule without a pharmacological active ingredient
Study NCT04490239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal heparin sodium (porcine)
Description: Intranasal heparin sodium
Study NCT03625934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VVX001
Description: 5 s.c. injections of 20 micrograms of VVX001 four weeks apart
Study NCT03625934 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 s.c. injections of matching Placebo four weeks apart
Study NCT02542982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Endomed 482; Enraf-Nonius B.V.)
Description: non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
Study NCT02542982 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (Endomed 482; Enraf-Nonius B.V.)
Description: non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
Study NCT02590926 — intervention group
Intervention type: PROCEDURE
Intervention: Fractional Flow Reserve, Myocardial
Description: The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
Study NCT04439344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT01035580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
Study NCT01035580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: all patients received the drug
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel (Taxotere®)
Description: 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone (pre- and post-medication for docetaxel)
Description: As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
Study NCT00532155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (pre- and post-medication for docetaxel)
Description: As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
Study NCT00402272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT01485393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
Study NCT01485393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
Study NCT03204227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
Study NCT03204227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
Study NCT02769650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medicamentous treatment
Study NCT02769650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress-MRI
Description: A standard stress-MRI test with adenosine
Study NCT02769650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress-MRI
Description: A standard stress-MRI test with adenosine
Study NCT02773940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
Study NCT01333917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin C3 tablet
Description: 4 grams Curcumin C3 tablet daily x30 days
Study NCT01876953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01876953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT01876953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study NCT01876953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02419573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
Study NCT02419573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube (King)
Description: In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
Study NCT04214288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally.
Study NCT04214288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Study NCT04323722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Empty Bladder planning CT scan and CBCTs
Description: Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
Study NCT03205501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-administation of EMI-137
Description: Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
Study NCT03205501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Study NCT02959840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure Point P6 stimulator
Description: This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
Study NCT02959840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
Study NCT02959840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
Study NCT03348488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltration dose
Description: Fixed high volume of ultrafiltration over an hour during dialysis
Study NCT01136928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips SmartSleep Technology--Continuous Fixed Interval modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SmartSleep Technology--Continuous Fixed Interval modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips SmartSleep Technology--Block modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SmartSleep Technology--Block modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips SmartSleep Technology--In-Phase Adjustable modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT03911154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SmartSleep Technology--In-Phase Adjustable modality
Description: During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband
Study NCT02853344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04378127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
Study NCT03011619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Standard of Care
Description: medication management, group therapy, and individual therapy.
Study NCT03011619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standard of Care
Description: medication management, group therapy, and individual therapy.
Study NCT03011619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Condition (CBT)
Description: CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
Study NCT02385370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
Study NCT02385370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: 0.1 cc of 0.01% MMC is injected into the tenon.
Study NCT03392077 — intervention group
Intervention type: PROCEDURE
Intervention: Caesarean section
Description: Caesarean section will be done to deliver the baby
Study NCT03392077 — intervention group
Intervention type: OTHER
Intervention: cervical dilatation
Description: Cervical dilatation will be done by double gloves digital dilatation postpartum
Study NCT01512394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard bowel prep
Description: standard bowel prep